Last updated on June 2009

Effect on Metabolic Parameters of Abilify in SPR


Brief description of study

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

Detailed Study Description

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Clinical Study Identifier: NCT00569764

Contact Investigators or Research Sites near you

Start Over

Jong-il Lee, M.D., Ph.D.

Seoul National Hospital
Seoul, Korea, Republic of
0.98miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.